Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
      Description

      This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)

      Conditions
      Solid Tumours Harboring NRG1 FusionNSCLC Harboring NRG1 FusionPancreatic Cancer Harboring NRG1 FusionNRG1 Fusion
      Talk to us
      ACTIVE_NOT_RECRUITING
      Study Evaluating Zenocutuzumab in Patients with or Without Molecularly Defined Cancers
      Description

      This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC

      Conditions
      NSCLC Harboring NRG1 FusionMetastatic Castration-resistant Prostate Cancer
      Talk to us
      TERMINATED
      Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
      Description

      Open-label, Phase 2, single treatment arm, 3 cohorts

      Conditions
      NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIICNSCLC, RecurrentEGFR Exon 20 Insertion MutationHER2-activating MutationERBB FusionNRG1 Fusion
      Talk to us
      TERMINATED
      Study of Seribantumab in Adult Patients with NRG1 Gene Fusion Positive Advanced Solid Tumors
      Description

      This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

      Conditions
      Locally Advanced Solid TumorMetastatic Solid TumorPancreatic CancerLung CancerHead and Neck CancerBreast CancerKidney CancerColorectal CancerBladder CancerOvarian CancerSarcomaGallbladder CancerBile Duct CancerEsophageal CancerUterine CancerCholangiocarcinomaProstate Cancer
      Talk to us